Advertisement
Screener

Dyne Therapeutics, Inc. (DYN) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Dyne Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Dyne Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $403.21M went out.
  • Fiscal year ended 2025-12-31: from investing, $28.75M went out.
  • Fiscal year ended 2025-12-31: from financing, $890.31M came in.
  • Fiscal year ended 2025-12-31: change in cash, $458.35M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2025-12-31-$403.21M-$28.75M$148.26M$140.65M$601.40M*$458.35M
2024-12-31-$292.37M-$204.08M$0.00$97.87M$712.02M*$313.45M
2023-12-31-$188.16M$83.31M$0.00$52.37M$1.95M*-$50.52M
2022-12-31-$153.65M$87.20M$36.86M$529.00K*-$29.05M
2021-12-31-$119.56M-$137.89M$584.00K$157.24M*-$99.63M
2020-12-31-$46.51M-$45.66M-$10.00M$9.94M$30.00K$380.72M*$288.52M
2019-12-31-$11.83M-$1.65M$19.99M*$6.51M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew debtNew shares soldNot split outChange in cash
2026-06-30-$130.29M*-$4.79M*$0.00*$58.11M*
2026-03-31-$144.92M-$2.39M$0.00$7.06M*-$140.25M
2025-12-31-$111.83M*$982.00K*$49.45M*$0.00*$381.51M*
2025-09-30-$90.78M*-$37.97M*$0.00*$0.00*$217.33M*
2025-06-30-$94.70M*$6.77M*$0.00*$100.77M*
2025-03-31-$105.89M$1.46M$140.65M$588.00K*$36.81M
2024-12-31-$84.33M*-$16.01M*$0.00*$0.00*$3.64M*
2024-09-30-$74.63M*-$19.40M*$0.00*$0.00*$18.01M*
2024-06-30-$54.87M*$11.17M*$24.25M*$355.61M*
2024-03-31-$78.54M-$179.84M$73.62M$334.77M*$150.01M
2023-12-31-$35.01M*$26.20M*-$1.00K*
2023-09-30-$50.60M*$12.82M*$0.00*
2023-06-30-$55.64M*$17.23M*$24.14M*$764.00K*
2023-03-31-$46.91M$27.06M$28.23M$587.00K*$8.97M
2022-12-31-$29.19M*$19.24M*$342.00K*$36.86M*
2022-09-30-$42.80M*$51.66M*$70.00K*
2022-06-30-$30.91M*$18.44M*$99.00K*
2022-03-31-$50.74M-$2.14M$18.00K-$52.86M
2021-12-31-$28.07M*-$235.00K*$89.00K*
2021-09-30-$26.95M*-$2.85M*$457.00K*
2021-06-30-$46.15M*-$6.43M*$25.00K*
2021-03-31-$18.39M-$128.38M$13.00K$157.24M*$10.48M
2020-12-31-$20.04M*-$45.22M*$0.00*$6.00K*-$11.20M*
2020-09-30-$11.89M*-$156.00K*$0.00*$379.98M*
2020-06-30-$7.30M*-$71.00K*$0.00*
2020-03-31-$7.29M-$211.00K$9.94M$1.97M*$4.41M
2019-12-31-$4.01M*-$737.00K*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Disc Medicine, Inc. (IRON)United States$2.553B-11.40